Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
The Lag3 inhibitor is now approved in melanoma, but Bristol looks unlikely to stop there in its search for a safer Yervoy.
Can a trial carried out in China back a US approval? Investors in anti-PD-(L)1 players will find out soon enough.
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
A handful of small caps, including Sensei and PDS, jumped on Asco abstract data, with much more news to come.
The Relativity-047 study shows that relatlimab has a big safety advantage over Yervoy, with just a slight decrease in clinical benefit.
Key catalysts approach for Orphazyme, Gemini and Immutep.
Next week’s virtual meeting could resuscitate Ox40 agonists, but an important omission will disappoint.